Market Place
Sourcing Support
All News #Library
Biotech
Nurix Therapeutics To Participate In Upcoming Investor Conference
07 Apr 2026 //
GLOBENEWSWIRE
Nurix Therapeutics Showcases Research Pipeline At (AACR) 2026
23 Mar 2026 //
GLOBENEWSWIRE
Nurix Therapeutics Reveals 2025 Financials And Corporate Update
28 Jan 2026 //
GLOBENEWSWIRE
Nurix Therapeutics Joins 44Th J.P. Morgan Healthcare Conference
05 Jan 2026 //
GLOBENEWSWIRE
Nurix Presents Bexobrutideg Data in Waldenström at ASH
08 Dec 2025 //
GLOBENEWSWIRE
Nurix Shows Strong Responses In Phase 1 Bexobrutideg Trial
06 Dec 2025 //
GLOBENEWSWIRE
Nurix Therapeutics To Present Phase 1 Bexobrutideg Data At ASH
01 Dec 2025 //
GLOBENEWSWIRE
Nurix Therapeutics Joins Piper Sandler Healthcare Conference
25 Nov 2025 //
GLOBENEWSWIRE
Nurix Trims Staff As Trial For Lead BTK Degrader Kicks Off
21 Nov 2025 //
FIERCE BIOTECH
Nurix Therapeutics Reveals Immune Activation Data For Oral CBL-B
07 Nov 2025 //
GLOBENEWSWIRE
Nurix Therapeutics To Join Investor Conferences
30 Oct 2025 //
GLOBENEWSWIRE
Nurix Therapeutics Completes $250M Common Stock Offering
27 Oct 2025 //
GLOBENEWSWIRE
Nurix Starts DAYBreak Pivotal Trial in Relapsed CLL Patients
22 Oct 2025 //
GLOBENEWSWIRE
Nurix Therapeutics Unveils NX-1607, Data Showing Efficacy
18 Oct 2025 //
GLOBENEWSWIRE
Nurix Unveils Preclinical Data on IRAK4 Degrader GS-6791
17 Sep 2025 //
GLOBENEWSWIRE
Sanofi Extends License for Nurix`s STAT6 program
02 Jun 2025 //
PRESS RELEASE
Sanofi pays Nurix $15M upfront for autoimmune degrader
03 Apr 2025 //
PRESS RELEASE
Nurix To Attend ADC & Radiopharmaceuticals Partnering Summit
06 Sep 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.